Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
McKesson
McKinsey
Express Scripts

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ETOPOSIDE PHOSPHATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Etoposide Phosphate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002880 ↗ Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 1996-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed non-Hodgkin's lymphoma.
NCT00002880 ↗ Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed Alliance for Clinical Trials in Oncology Phase 2 1996-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed non-Hodgkin's lymphoma.
NCT00002961 ↗ Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia Terminated Children's Hospital of Philadelphia Phase 3 1995-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy, radiation therapy, and bone marrow transplantation may kill more cancer cells. PURPOSE: Randomized phase III trial to compare high-dose chemotherapy with or without total-body irradiation before bone marrow transplantation in treating children with acute lymphoblastic leukemia.
NCT00003064 ↗ Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Unknown status National Cancer Institute (NCI) Phase 1/Phase 2 1997-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and autologous peripheral stem cell transplantation in treating patients with recurrent or persistent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer.
NCT00003064 ↗ Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Unknown status Herbert Irving Comprehensive Cancer Center Phase 1/Phase 2 1997-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy and autologous peripheral stem cell transplantation in treating patients with recurrent or persistent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer.
NCT00005792 ↗ Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed Bristol-Myers Squibb Phase 1 1998-06-02 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have multiple myeloma.
NCT00005792 ↗ Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed SmithKline Beecham Phase 1 1998-06-02 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etoposide Phosphate

Condition Name

Condition Name for Etoposide Phosphate
Intervention Trials
Lymphoma 17
Leukemia 10
Neuroblastoma 7
Brain and Central Nervous System Tumors 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Etoposide Phosphate
Intervention Trials
Lymphoma 38
Leukemia 27
Leukemia, Lymphoid 15
Hodgkin Disease 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Etoposide Phosphate

Trials by Country

Trials by Country for Etoposide Phosphate
Location Trials
United States 725
Canada 62
United Kingdom 28
Australia 26
Germany 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Etoposide Phosphate
Location Trials
California 35
Texas 30
Ohio 27
Pennsylvania 25
Missouri 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Etoposide Phosphate

Clinical Trial Phase

Clinical Trial Phase for Etoposide Phosphate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 21
Phase 2/Phase 3 2
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Etoposide Phosphate
Clinical Trial Phase Trials
Completed 34
Recruiting 19
Active, not recruiting 17
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Etoposide Phosphate

Sponsor Name

Sponsor Name for Etoposide Phosphate
Sponsor Trials
National Cancer Institute (NCI) 45
Children's Oncology Group 8
City of Hope Medical Center 7
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Etoposide Phosphate
Sponsor Trials
Other 98
NIH 45
Industry 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
Express Scripts
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.